New review sharpens guidance on at-home oral pain control

Version 2 — Full analysis

A new peer-reviewed CE article in Today’s Veterinary Practice puts a sharper point on a familiar clinical problem: what should dogs and cats actually go home with when they need short-term pain control. In “Management of Acute Pain at Home: Oral Analgesics for Dogs and Cats,” published February 12, 2026, Sarah Shippy, DVM, MPH, MS, DACVAA, concludes that NSAIDs remain the most consistent oral analgesics for acute pain in small animal practice, while commonly used alternatives such as oral opioids, gabapentinoids, and amantadine have weaker evidence, especially as sole agents. (todaysveterinarypractice.com)

That message fits with the broader direction of companion animal pain guidance over the last several years. AAHA’s 2022 pain management guidelines emphasize thorough pain assessment, multimodal treatment, individualized dosing, monitoring, and client education, rather than relying on any one drug class as a universal answer. The guidelines also frame pain management as a team responsibility that extends beyond the hospital stay, which is especially relevant when patients are discharged before inflammation and sensitization have fully resolved. (aaha.org)

Shippy’s article makes the case that acute postsurgical pain is fundamentally inflammatory, so the best oral drugs are those that address both pain and inflammation. In that context, NSAIDs remain the backbone for many canine and feline patients, though not without screening and monitoring. The article also walks through why some commonly prescribed alternatives fall short: oral opioid derivatives such as tramadol, codeine, and hydrocodone have poor oral bioavailability in dogs and cats, tramadol appears to have low efficacy for postoperative pain in dogs, and gabapentin’s evidence in acute pain is mixed enough that it’s better viewed as an adjunct than a replacement for primary analgesia. Amantadine is discussed in a similar adjunctive light rather than as a dependable first-line oral choice for acute postoperative pain. Transmucosal buprenorphine, while technically distinct from oral dosing, remains a practical at-home option, particularly in cats. (todaysveterinarypractice.com)

Regulatory and safety context reinforces that approach. FDA guidance for veterinarians and pet parents continues to stress that approved veterinary NSAIDs can provide meaningful pain relief when used carefully, but that risk rises in patients that are dehydrated, receiving corticosteroids or certain other drugs, or have underlying kidney, liver, or heart disease. The agency also warns against pet parents substituting human over-the-counter pain relievers without veterinary direction, an issue that becomes more important as more pain management shifts into the home setting. (fda.gov)

The article also lands at a moment when veterinary teams are paying closer attention to the operational side of prescribing. A recent Instinct post aimed at hospital teams argues that prescribing often feels harder than it should because clinicians are juggling dose checks, calculations, unit conversions, tablet or liquid rounding, and interaction screening while moving in and out of the PIMS and drug references—and doing it all in an interruption-heavy environment. The post cites human healthcare research finding frequent prescribing interruptions and links those disruptions to higher error rates, which helps explain why even routine discharge medications can create outsized mental load for veterinarians and staff. While the piece is product-oriented, it reflects a real workflow issue: safer prescribing is not only about choosing the right analgesic, but also about reducing avoidable cognitive burden during the prescribing process. (instinct.vet)

Why it matters: For veterinary professionals, the practical takeaway isn’t simply “use NSAIDs more.” It’s that acute pain plans for home use should be built around the underlying pain mechanism, the species involved, the pet parent’s ability to administer the medication, and the clinic’s ability to provide clear instructions and follow-up. In dogs, that may mean being more skeptical of tramadol as a default discharge drug. In cats, it may mean leaning on feline-specific strategies, including transmucosal buprenorphine when appropriate, while recognizing administration challenges and contraindications. More broadly, the piece supports a more disciplined approach to multimodal analgesia: NSAIDs where appropriate, adjuncts where evidence supports them, and better client counseling about what pain, sedation, GI upset, or adverse effects look like at home. It also supports more standardized prescribing steps inside the clinic, since interruptions, fragmented dose calculations, and switching between systems can all make routine discharge analgesia less reliable than it appears on paper. (todaysveterinarypractice.com)

There’s also an education angle. The article appears in a peer-reviewed CE format and stays close to the evidence, including the limitations of existing studies. That’s useful in a category where habit, anecdote, and convenience can still influence prescribing. For teams under pressure to discharge efficiently, the combination of evidence-based drug selection, species-appropriate administration strategies, and cleaner prescription workflows may be just as important as the drug choice itself. (todaysveterinarypractice.com)

What to watch: The next area to watch is whether stronger comparative data emerge for common oral adjuncts, especially gabapentinoids and other non-NSAID options, and whether practices translate that evidence into more standardized discharge protocols, client education tools, and prescribing systems that reduce interruption-related friction without compromising safety. (todaysveterinarypractice.com)